Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse...
Dermatology
Intravenous ertapenem for hidradenitis suppurativa
1. Intravenous ertapenem administered for a mean of 13 weeks for patients with hidradenitis suppurativa was associated with improvement in...
Individualized cancer mRNA-based cancer therapy shows benefit in patients with high-risk melanoma on immunotherapy
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no...
Radiation treatment for breast cancer may increase incidence of nonkeratinocyte skin cancer
1. Amongst a cohort of breast cancer survivors, those that were treated with radiation had a higher risk of developing...
Interleukin-23 receptor antagonist improves psoriasis symptoms
1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed...
First-line rituximab for pemphigus associated with long-term complete remission rates
1. Patients with pemphigus treated with first-line rituximab showed sustained complete remission rates without corticosteroids for up to 7 years...
IL-23 inhibitors may have a lower risk of paradoxical eczema in comparison to other biologics
1. Interleukin-23 inhibitors had a lower risk of developing paradoxical eczema when treated for plaque psoriasis compared to TNF inhibitors,...
Current expert consensus for the treatment of adult patients with drug reaction with eosinophilia and systemic symptoms
1. A large majority of experts in this study came to a unified consensus on how to approach the diagnosis...
Spesolimab may improve quality of life in patients with generalized pustular psoriasis flares
1. Efficacy of spesolimab appeared to be dose-dependent with high-dose spesolimab leading to a significantly longer time to GPP flare-up...
3-dimensional stereophotogrammetry for craniofacial morphea disease progression
1. 3-dimensional (3D) stereophotogrammetry identified craniofacial morphea (CM) progression in patients with clinically reported disease activity. 2. 3D stereophotogrammetry identified...
